Google
SCNI — SCINAI IMMUNOTHERAPEUTICS LTD (Healthcare >> Biotechnology)
SCNI FAQ
What is SCNI's ROE?
SCINAI IMMUNOTHERAPEUTICS LTD reports a Return on Equity (ROE) of -102.52%.
What is SCNI's dividend yield?
SCINAI IMMUNOTHERAPEUTICS LTD offers a dividend yield of 0.00%.
What is SCNI's Deepscope Quality Score?
Deepscope rates SCNI's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SCNI?
Deepscope's AI Timing Score for SCNI is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SCNI belong to?
SCINAI IMMUNOTHERAPEUTICS LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.45
Price
-0.03
(-5.43%)
Day Change
|
|
|---|
SCNI, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 85 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.45 |
| PBV / Sector |
0.23 / 4.48
GREAT
|
| Earning Per Share | -2.06 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.11 M
GREAT
|
| Average 1W Daily Value |
0.12 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:23:59 |
| Symbol | SCNI |
| Name | SCINAI IMMUNOTHERAPEUTICS LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 3.96 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1.82 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Jerusalem BioPark, Jerusalem, Israel
Phone: 972 8 930 2529
Website: https://www.scinai.com
Sector: Healthcare >> Biotechnology
Description: Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
